NEURACEQ Drug Patent Profile
✉ Email this page to a colleague
When do Neuraceq patents expire, and what generic alternatives are available?
Neuraceq is a drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-five patent family members in twenty-seven countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Neuraceq
Neuraceq was eligible for patent challenges on March 21, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 18, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NEURACEQ
International Patents: | 35 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 6 |
Patent Applications: | 105 |
What excipients (inactive ingredients) are in NEURACEQ? | NEURACEQ excipients list |
DailyMed Link: | NEURACEQ at DailyMed |

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NEURACEQ
Generic Entry Date for NEURACEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NEURACEQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Life Molecular Imaging GmbH | Phase 3 |
William Charles Kreisl | Phase 1/Phase 2 |
Ulsan University Hospital | N/A |
Pharmacology for NEURACEQ
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for NEURACEQ
NEURACEQ is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NEURACEQ is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NEURACEQ
Stilbene derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Life Molecular | NEURACEQ | florbetaben f-18 | SOLUTION;INTRAVENOUS | 204677-001 | Mar 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEURACEQ
When does loss-of-exclusivity occur for NEURACEQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 05316421
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0516408
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 91534
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1123995
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 06
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 13652
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 2334
Estimated Expiration: ⤷ Try a Trial
Patent: 0701299
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 38298
Estimated Expiration: ⤷ Try a Trial
Patent: 41465
Estimated Expiration: ⤷ Try a Trial
Patent: 13652
Estimated Expiration: ⤷ Try a Trial
France
Patent: C0012
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 500014
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 3946
Estimated Expiration: ⤷ Try a Trial
Patent: 6091
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 28956
Estimated Expiration: ⤷ Try a Trial
Patent: 08524243
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 213652
Estimated Expiration: ⤷ Try a Trial
Luxembourg
Patent: 647
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 07007380
Estimated Expiration: ⤷ Try a Trial
Netherlands
Patent: 0719
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 5942
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 9195
Estimated Expiration: ⤷ Try a Trial
Patent: 073650
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 13652
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 13652
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 4363
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 13652
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 0705104
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1321619
Estimated Expiration: ⤷ Try a Trial
Patent: 070093427
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 26655
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 996
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NEURACEQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1838298 | Dérivés du stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et pour se lier à elles (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES) | ⤷ Try a Trial |
China | 100493142 | ⤷ Try a Trial | |
Japan | 2008524243 | ⤷ Try a Trial | |
European Patent Office | 1841465 | DERIVES DE STILBENE ET LEUR UTILISATION POUR LA LIAISON ET L'IMAGERIE DE PLAQUES AMYLOIDES (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NEURACEQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2213652 | 504 | Finland | ⤷ Try a Trial | |
2213652 | C02213652/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66210 23.08.2017 |
2213652 | 15C0012 | France | ⤷ Try a Trial | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224 |
2213652 | CA 2015 00018 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140220 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |